184 related articles for article (PubMed ID: 32611642)
21. Adding quantitative muscle MRI to the FSHD clinical trial toolbox.
Mul K; Vincenten SCC; Voermans NC; Lemmers RJLF; van der Vliet PJ; van der Maarel SM; Padberg GW; Horlings CGC; van Engelen BGM
Neurology; 2017 Nov; 89(20):2057-2065. PubMed ID: 29030457
[TBL] [Abstract][Full Text] [Related]
22. Quantifying disease activity in fatty-infiltrated skeletal muscle by IDEAL-CPMG in Duchenne muscular dystrophy.
Mankodi A; Bishop CA; Auh S; Newbould RD; Fischbeck KH; Janiczek RL
Neuromuscul Disord; 2016 Oct; 26(10):650-658. PubMed ID: 27593185
[TBL] [Abstract][Full Text] [Related]
23. Muscle fibrosis as a prognostic biomarker in facioscapulohumeral muscular dystrophy: a retrospective cohort study.
Ragozzino E; Bortolani S; Di Pietro L; Papait A; Parolini O; Monforte M; Tasca G; Ricci E
Acta Neuropathol Commun; 2023 Oct; 11(1):165. PubMed ID: 37849014
[TBL] [Abstract][Full Text] [Related]
24. The magnetic resonance imaging spectrum of facioscapulohumeral muscular dystrophy.
Friedman SD; Poliachik SL; Carter GT; Budech CB; Bird TD; Shaw DW
Muscle Nerve; 2012 Apr; 45(4):500-6. PubMed ID: 22431082
[TBL] [Abstract][Full Text] [Related]
25. Specific muscle strength is reduced in facioscapulohumeral dystrophy: An MRI based musculoskeletal analysis.
Marra MA; Heskamp L; Mul K; Lassche S; van Engelen BGM; Heerschap A; Verdonschot N
Neuromuscul Disord; 2018 Mar; 28(3):238-245. PubMed ID: 29395674
[TBL] [Abstract][Full Text] [Related]
26. Muscle diffusion tensor imaging in facioscapulohumeral muscular dystrophy.
Barzaghi L; Paoletti M; Monforte M; Bortolani S; Bonizzoni C; Thorsten F; Bergsland N; Santini F; Deligianni X; Tasca G; Ballante E; Figini S; Ricci E; Pichiecchio A
Muscle Nerve; 2024 Aug; 70(2):248-256. PubMed ID: 38873946
[TBL] [Abstract][Full Text] [Related]
27. Dynamic magnetic resonance imaging of muscle contraction in facioscapulohumeral muscular dystrophy.
Deligianni X; Santini F; Paoletti M; Solazzo F; Bergsland N; Savini G; Faggioli A; Germani G; Monforte M; Ricci E; Tasca G; Pichiecchio A
Sci Rep; 2022 May; 12(1):7250. PubMed ID: 35508609
[TBL] [Abstract][Full Text] [Related]
28. Long-term follow-up of MRI changes in thigh muscles of patients with Facioscapulohumeral dystrophy: A quantitative study.
Fatehi F; Salort-Campana E; Le Troter A; Lareau-Trudel E; Bydder M; Fouré A; Guye M; Bendahan D; Attarian S
PLoS One; 2017; 12(8):e0183825. PubMed ID: 28841698
[TBL] [Abstract][Full Text] [Related]
29. A quantitative method to assess muscle edema using short TI inversion recovery MRI.
Dahlqvist JR; Salim R; Thomsen C; Vissing J
Sci Rep; 2020 Apr; 10(1):7246. PubMed ID: 32350361
[TBL] [Abstract][Full Text] [Related]
30. Adapting MRI as a clinical outcome measure for a facioscapulohumeral muscular dystrophy trial of prednisone and tacrolimus: case report.
Wang LH; Johnstone LM; Bindschadler M; Tapscott SJ; Friedman SD
BMC Musculoskelet Disord; 2021 Jan; 22(1):56. PubMed ID: 33422031
[TBL] [Abstract][Full Text] [Related]
31. Muscle MRI of facioscapulohumeral dystrophy (FSHD): A growing demand and a promising approach.
Fatehi F; Salort-Campana E; Le Troter A; Bendahan D; Attarian S
Rev Neurol (Paris); 2016 Oct; 172(10):566-571. PubMed ID: 27663058
[TBL] [Abstract][Full Text] [Related]
32. Repeatability of Dixon magnetic resonance imaging and magnetic resonance spectroscopy for quantitative muscle fat assessments in the thigh.
Grimm A; Meyer H; Nickel MD; Nittka M; Raithel E; Chaudry O; Friedberger A; Uder M; Kemmler W; Engelke K; Quick HH
J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1093-1100. PubMed ID: 30221479
[TBL] [Abstract][Full Text] [Related]
33. Refining the spinobulbar muscular atrophy phenotype by quantitative MRI and clinical assessments.
Dahlqvist JR; Oestergaard ST; Poulsen NS; Thomsen C; Vissing J
Neurology; 2019 Feb; 92(6):e548-e559. PubMed ID: 30610091
[TBL] [Abstract][Full Text] [Related]
34. Whole-body magnetic resonance imaging evaluation of facioscapulohumeral muscular dystrophy.
Leung DG; Carrino JA; Wagner KR; Jacobs MA
Muscle Nerve; 2015 Oct; 52(4):512-20. PubMed ID: 25641525
[TBL] [Abstract][Full Text] [Related]
35. Skeletal Muscle Magnetic Resonance Biomarkers in GNE Myopathy.
Liu CY; Yao J; Kovacs WC; Shrader JA; Joe G; Ouwerkerk R; Mankodi AK; Gahl WA; Summers RM; Carrillo N
Neurology; 2021 Feb; 96(5):e798-e808. PubMed ID: 33219145
[TBL] [Abstract][Full Text] [Related]
36. [Skeletal muscle MRI of lower limbs in patients with facioscapulohumeral dystrophy].
Ma MM; Song J; Zhang JW; Gao L; Pang M; Li G; Fu J
Zhonghua Yi Xue Za Zhi; 2019 Mar; 99(9):675-679. PubMed ID: 30831616
[No Abstract] [Full Text] [Related]
37. Quantitative muscle ultrasound versus quantitative magnetic resonance imaging in facioscapulohumeral dystrophy.
Janssen BH; Pillen S; Voet NB; Heerschap A; van Engelen BG; van Alfen N
Muscle Nerve; 2014 Dec; 50(6):968-75. PubMed ID: 24659533
[TBL] [Abstract][Full Text] [Related]
38. Muscle Microdialysis to Investigate Inflammatory Biomarkers in Facioscapulohumeral Muscular Dystrophy.
Tasca G; Monforte M; Corbi M; Granata G; Lucchetti D; Sgambato A; Ricci E
Mol Neurobiol; 2018 Apr; 55(4):2959-2966. PubMed ID: 28456937
[TBL] [Abstract][Full Text] [Related]
39. Multivoxel proton magnetic resonance spectroscopy in facioscapulohumeral muscular dystrophy.
Leung DG; Wang X; Barker PB; Carrino JA; Wagner KR
Muscle Nerve; 2018 Jun; 57(6):958-963. PubMed ID: 29266323
[TBL] [Abstract][Full Text] [Related]
40. Muscle strength, quantity and quality and muscle fat quantity and their association with oxidative stress in patients with facioscapulohumeral muscular dystrophy: Effect of antioxidant supplementation.
Wilson VD; Bommart S; Passerieux E; Thomas C; Pincemail J; Picot MC; Mercier J; Portet F; Arbogast S; Laoudj-Chenivesse D
Free Radic Biol Med; 2024 Jul; 219():112-126. PubMed ID: 38574978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
